Document text
Principal Investigator: Kathryn M. Anastos
Organization: ALBERT EINSTEIN COLLEGE OF MEDICINE
Fiscal Year: 2021
Award: $40,374
Funding agency: National Heart Lung and Blood Institute
COVID Vaccine Study Supplement to MWCCS Principal Investigators: C. Rinaldo and J. Martinson
Innovation Fund Application to the Multicenter AIDS Cohort Study (MACS)/Women’s
Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS): COVID-19 Vaccine Acceptance
and Hesitancy (CVHB) Study in People with HIV
Scientific Justification
A safe, highly immunogenic vaccine to prevent primary SARS-CoV-2 infection is needed to control the
COVID-19 pandemic. As of January, 2021, the United States is racing to vaccinate a significant
percentage of our 330 million population to control the COVID-19 pandemic. This extraordinary rapid
development resulted from FDA emergency use authorization (EUA) of two COVID-19 vaccines in
December, 2020, i.e., the Moderna mRNA-1273 vaccine that codes for the stabilized pre-fusion SARS-
CoV-2 spike protein 1, and the Pfizer/BioNTech vaccine BNT162b1 that is a lipid-nanoparticle-formulated,
nucleoside-modified mRNA vaccine that encodes the trimerized receptor-binding domain of the spike
glycoprotein of SARS-CoV-2 2.
Despite this enormous public health issue of stopping the COVID-19 pandemic, there are essentially no
data on COVID-9 vaccine acceptance or efficacy in people with HIV (PWH). This is critically important
for public health, in that an estimated 1.2 million people aged 13 and older have HIV in the United States,
including an estimated 161,800 (14%) people whose infections had not been diagnosed 3. Although
several COVID-19 vaccine clinical efficacy trials enrolled PWH without specific selectivity, there are
insufficient data exist to determine the efficacy of COVID-19 vaccines in PWH. Indeed, prior to the
COVID-19 pandemic, the CDC recommended that PWH with CD4 T cell counts of ≥200 or percentages
≥15% receive all licensed vaccines. Further, the CDC stated in a release December 12, 2020
(https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-12/COVID-03-
Mbaeyi.pdf): “The recently FDA-authorized Pfizer-BioNTech COVID-19 vaccine is not contraindicated for
people living with HIV or others with immunocompromised conditions, though vaccine efficacy data
does not currently exist for potentially immunocompromised individuals”. According to the CDC
Advisory Committee on Immunization Practices (ACIP), “people living with HIV may still receive the
vaccine, but should be counseled on unknown vaccine safety and efficacy profiles in
immunocompromised persons.” The ACIP also recently recommended that health care personnel and
residents of long-term care facilities (LTCFs) be offered vaccination in the initial phase of the COVID-19
vaccination program (Phase 1a) 4. In sum, PWH are looking to us for advice as their scientific and
clinical HIV experts, with our response being that the COVID-19 vaccines “should be” safe and
effective in them based on no specific data. Our proposed study aims to supply such data through
a well-designed protocol nested in the most well-established and trusted MACS-WIHS Combined
Cohort Study (MWCCS).
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><21+ years old><4-dimensional><AACTG><ACTG><AIDS><AIDS Virus><AIDS clinical trial group><Academy><Aching muscles><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immuno-Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Acquired Immunologic Deficiency Syndrome><Active Follow-up><Addendum><Address><Administrative Supplement><Adult><Adult Human><Advisory Committees><Affect><Age><Aging><American><Antibody titer measurement><Area><Asians><Attenuated><Attitude><Awareness><BMI><BMI percentile><BMI z-score><BNT162b2><Back><Bar Codes><Behavior><Behavioral><Behavioral Medicine><Biological><Black race><Blood><Blood Donations><Blood Reticuloendothelial System><Blood Sample><Blood Serum><Blood specimen><Body mass index><Budgets><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CDC><COPD><COVID><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 S protein><COVID-19 associated death><COVID-19 associated fatality><COVID-19 associated mortality><COVID-19 crisis><COVID-19 death><COVID-19 disease severity><COVID-19 epidemic><COVID-19 fatality><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 induced death><COVID-19 induced fatality><COVID-19 induced mortality><COVID-19 infection><COVID-19 mortality><COVID-19 pandemic><COVID-19 positive><COVID-19 positivity><COVID-19 prevention><COVID-19 public health crisis><COVID-19 related death><COVID-19 related fatality><COVID-19 related mortality><COVID-19 severity><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 surveillance><COVID-19 test><COVID-19 tests><COVID-19 therapy><COVID-19 transmission><COVID-19 treatment><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID-19 virus transmission><COVID19><COVID19 S protein><COVID19 associated death><COVID19 associated fatality><COVID19 associated mortality><COVID19 crisis><COVID19 death><COVID19 disease severity><COVID19 epidemic><COVID19 fatality><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 induced death><COVID19 induced fatality><COVID19 induced mortality><COVID19 infection><COVID19 mortality><COVID19 pandemic><COVID19 positive><COVID19 positivity><COVID19 prevention><COVID19 public health crisis><COVID19 related death><COVID19 related fatality><COVID19 related mortality><COVID19 severity><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 surveillance><COVID19 test><COVID19 tests><COVID19 therapy><COVID19 treatment><COVID19 vaccination><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cancers><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Caring><Categories><Cell Count><Cell Number><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Cephalalgia><Cephalgia><Cephalodynia><Cessation of life><Characteristics><Chicago><Chills><Chronic><Chronic Obstruction Pulmonary Disease><Chronic Obstructive Airway Disease><Chronic Obstructive Lung Disease><Chronic Obstructive Pulmonary Disease><Clinic><Clinic Visits><Clinical><CoV disease><CoV-2><CoV2><Code><Coding System><Cognitive Discrimination><Cohort Studies><Collection><Communicable Diseases><Communication><Communities><Complement><Complement Proteins><Computers><Concurrent Studies><Confounding Factors (Epidemiology)><Confounding Variables><Consent><Consult><Coughing><Counseling><Cranial Pain><DNA><Data><Death><Decision Making><Deoxyribonucleic Acid><Development><Devices><Diabetes Mellitus><Diagnosis><Dimensions><Discrimination><Disease><Disorder><Dorsum><Dose><Drugs><Dyslipidemias><E-Mail><East Indies><Economic Income><Economical Income><Economics><Elderly><Electronic Mail><Eligibility><Eligibility Determination><Email><England><Enrollment><Epidemiologic Confounding Factor><Epidemiology><Equation><Ethnic Origin><Ethnicity><Europe><Evaluation><Event><FDA EUA><FDA Emergency Use Authorization><Family Practice><Feedback><Feeling><Female><Fever><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Fostering><Foundations><Four-dimensional><Funding><Future><Gender><Goals><Grafting Procedure><Grippe><Guidelines><Gustation><H1N1><H1N1 Virus><HIV><HIV Infections><HIV Seronegativities><HIV Seronegativity><HIV Vaccine Trials Network><HIV negative><HPV Vaccine><HTLV-III Infections><HTLV-III Seronegativities><HTLV-III Seronegativity><HTLV-III-LAV Infections><HVTN><Head Pain><Headache><Health><Health Care Providers><Health Facilities><Health Inequity><Health Personnel><Health Sciences><Health care facility><Healthcare Facility><Healthcare Providers><Healthcare worker><Heart Vascular><Hispanic Populations><Hispanics><History><Home><Hospital Admission><Hospitalization><Household><Human Immunodeficiency Viruses><Human Papilloma Virus Vaccine><Human T-Lymphotropic Virus Type III Infections><Human papillomavirus Vaccine><Hypertension><IRB><IRBs><Immune><Immune response><Immunes><Immunization><Immunization Programs><Immunize><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><Immunosuppressed Host><Incentives><Incidence><Income><Individual><Indonesia><Inequalities in Health><Inequities in Health><Infection><Infection Control><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza A Virus, H1N1 Subtype><Innate Immunity><Institutional Review Boards><Instruction><Intention><Intervention><Intervention Strategies><Interview><Investigation><Investigators><Joints><Journals><Kidney Diseases><LAV-HTLV-III><Label><Laboratories><Laboratory Study><Latino Population><Link><Literature><Location><Logistic Regressions><Long-Term Care><Longitudinal observation study><Longitudinal observational study><Lung><Lung Respiratory System><Lymphadenopathy-Associated Virus><MMR Vaccine><Magazine><Malay Archipelago><Malignant Neoplasms><Malignant Tumor><Measles><Measles-Mumps-Rubella Vaccine><Measurement><Measures><Mediating><Mediation><Mediator><Mediator of Activation><Mediator of activation protein><Medical><Medical Records><Medication><Medicine><Meta-Analysis><Methods><Misinformation><Modeling><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Monitor><Morbidity><Morbidity - disease rate><Movement><Muscle discomfort><Muscle pain><Muscle pain/fibrositis><Muscle sorenesss><Myalgia><Myalgic><Myodynia><Myoneuralgia><Myosalgia><NIH><Names><National Institutes of Health><Native Immunity><Natural Immunity><Nature><Negotiating><Negotiation><Nephropathy><Netherlands East Indies><New York><Non-Hispanic><Non-Specific Immunity><Nonhispanic><Nonspecific Immunity><Not Hispanic or Latino><Nucleosides><Obesity><Observation research><Observation study><Observational Study><Observational research><Olfaction><Organ Transplantation><Organ Transplants><Outcome><Painless><Participant><Pathway interactions><Patient Self-Report><Patients><Perception><Persons><Pfizer-BioNTech COVID-19 vaccine><Pfizer-BioNTech coronavirus disease 2019 vaccine><Pharmaceutic Preparations><Pharmaceutical Preparations><Pharmacies><Pharmacy facility><Phase><Phone><Population><Population Control><Population Heterogeneity><Prevalence><Prevention><Primary Care><Primary Health Care><Primary Healthcare><Principal Investigator><Proteins><Protocol><Protocol Screening><Protocols documentation><Provider><Public Health><Publications><Pyrexia><Questionnaires><Quetelet index><R-Series Research Projects><R01 Mechanism><R01 Program><RNA vaccine><RNA-based vaccine><Race><Racial Group><Racial Segregation><Racial Stocks><Recommendation><Recording of previous events><Renal Disease><Reporting><Research><Research Design><Research Grants><Research Methodology><Research Methods><Research Personnel><Research Project Grants><Research Projects><Research Specimen><Researchers><Respondent><Risk><Risk Factors><Rubeola><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 associated death><SARS-CoV-2 associated fatality><SARS-CoV-2 associated mortality><SARS-CoV-2 death><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 fatality><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 induced death><SARS-CoV-2 induced fatality><SARS-CoV-2 induced mortality><SARS-CoV-2 infection><SARS-CoV-2 mortality><SARS-CoV-2 pandemic><SARS-CoV-2 positive><SARS-CoV-2 positivity><SARS-CoV-2 related death><SARS-CoV-2 related fatality><SARS-CoV-2 related mortality><SARS-CoV-2 severity><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 surveillance><SARS-CoV-2 test><SARS-CoV-2 tests><SARS-CoV-2 therapy><SARS-CoV-2 transmission><SARS-CoV-2 treatment><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sample Size><Sampling><Schedule><Schools><Scientific Publication><Self Administration><Self-Administered><Self-Report><Series><Serology><Serum><Services><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 positive><Severe acute respiratory syndrome coronavirus 2 positivity><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severities><Shipping><Ships><Shortness of Breath><Site><Slide><Smell><Smell Perception><Smoking><Social Medicine><Social Sciences><Social status><Societies><Source><Spanish Origin><Specimen><Standardization><Structure><Study Type><Suggestion><Sum><Survey Instrument><Survey Method><Survey Methodology><Surveys><Swab><Symptoms><T4 Cells><T4 Lymphocytes><Target Populations><Task Forces><Taste><Taste Perception><Telephone><Temperature><Temporal trend><Testing><Text><The Multi-center AIDS Cohort Study><The Multicenter AIDS Cohort Study><Thinking><Time><Time trend><TimeLine><Titrations><Transplant Recipients><Trends over time><Trust><Typology><United States><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><United States National Institutes of Health><Universities><Urban Health><Vaccinated><Vaccination><Vaccination Programs><Vaccine Antigen><Vaccine Research><Vaccines><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Virus-HIV><Visit><Voice><Wolves><Woman><Women's Interagency HIV Study><Work><Wuhan coronavirus><accept vaccination><accept vaccine><access to vaccination><access to vaccines><acquired immunodeficiency syndrome clinical trial group><active followup><adiposity><adjudicate><adjudication><adjudicative process and procedure><adulthood><advanced age><advisory team><aged><ages><analytical method><anti-retroviral therapy><anti-retroviral treatment><antibody based test><antibody test><antibody titering><antiretroviral therapy><antiretroviral treatment><barcode><base><behavioral/social science><body movement><cardiovascular disorder><care facilities><circulatory system><clinical research site><clinical site><co-infection><co-morbid><co-morbidity><cohort><coinfection><common symptom><comorbidity><corona virus disease><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 associated death><coronavirus disease 2019 associated fatality><coronavirus disease 2019 associated mortality><coronavirus disease 2019 crisis><coronavirus disease 2019 death><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 fatality><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 induced death><coronavirus disease 2019 induced fatality><coronavirus disease 2019 induced mortality><coronavirus disease 2019 infection><coronavirus disease 2019 mortality><coronavirus disease 2019 pandemic><coronavirus disease 2019 positive><coronavirus disease 2019 positivity><coronavirus disease 2019 prevention><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related death><coronavirus disease 2019 related fatality><coronavirus disease 2019 related mortality><coronavirus disease 2019 severity><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 surveillance><coronavirus disease 2019 test><coronavirus disease 2019 tests><coronavirus disease 2019 therapy><coronavirus disease 2019 transmission><coronavirus disease 2019 treatment><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><corpulence><data centers><death due to COVID-19><death due to COVID19><death due to SARS-CoV-2><death due to coronavirus disease 2019><death due to severe acute respiratory syndrome coronavirus 2><death in COVID><death in COVID-19><death in SARS-CoV-2><death in coronavirus disease><death in coronavirus disease 2019><death in severe acute respiratory syndrome coronavirus 2><death risk><deploy vaccines><depository><design><designing><develop a vaccine><development of a vaccine><developmental><diabetes><disease phenotype><disparity in health><distribute vaccines><distrust><diverse populations><drug/agent><efficacy clinical trial><elders><electronic communication><emergency use authorization><enroll><epidemiologic><epidemiological><ethnic diversity><ethnically diverse><ethnoracial><experience><extended care><family medicine><fatality due to COVID-19><fatality due to COVID19><fatality due to SARS-CoV-2><fatality due to coronavirus disease 2019><fatality due to severe acute respiratory syndrome coronavirus 2><febrile><febris><feelings><flu><follow up><follow-up><followed up><followup><geriatric><global health><gustatory perception><gustatory processing><gustatory response><hCoV19><head ache><health care personnel><health care worker><health communication><health disparity><health inequalities><health provider><health workforce><healthcare personnel><hesitant to vaccination><heterogeneous population><high blood pressure><high risk><high risk group><high risk population><hispanic community><host response><hyperpiesia><hyperpiesis><hypertensive disease><immune system response><immunogenic><immunoresponse><immunosuppressed patient><improved><indexing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><insight><instrument><intersectionalities><intersectionality><interventional strategy><kidney disorder><late life><later life><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lipid nanoparticle><longterm care><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><male><malignancy><medical college><medical personnel><medical schools><meetings><men><men's><morbilli><mortality><mortality due to COVID-19><mortality due to COVID19><mortality due to SARS-CoV-2><mortality due to coronavirus disease 2019><mortality due to severe acute respiratory syndrome coronavirus 2><mortality risk><nCoV2><neoplasm/cancer><non-painful><nonpainful><not painful><odor perception><older adult><older person><olfactory perception><on-line community><online community><organ allograft><organ graft><organ xenograft><outreach><pandemic><pandemic disease><pathway><phase 3 trial><phase III trial><population diversity><preference><prevent><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><preventing><prospective><protective effect><psychologic><psychological><psychosocial><pulmonary><race differences><racial and ethnic><racial difference><racial diversity><racially diverse><receptor binding><receptor bound><recruit><renal disorder><repository><response><response to treatment><school of medicine><segregation><senior citizen><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><seroconversion><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 associated death><severe acute respiratory syndrome coronavirus 2 associated fatality><severe acute respiratory syndrome coronavirus 2 associated mortality><severe acute respiratory syndrome coronavirus 2 death><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 fatality><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced death><severe acute respiratory syndrome coronavirus 2 induced fatality><severe acute respiratory syndrome coronavirus 2 induced mortality><severe acute respiratory syndrome coronavirus 2 mortality><severe acute respiratory syndrome coronavirus 2 related death><severe acute respiratory syndrome coronavirus 2 related fatality><severe acute respiratory syndrome coronavirus 2 related mortality><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 surveillance><severe acute respiratory syndrome coronavirus 2 test><severe acute respiratory syndrome coronavirus 2 tests><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 transmission><severe acute respiratory syndrome coronavirus 2 treatment><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sex><side effect><social><social media><social position><social science research><social standing><social stigma><socio-demographic predictors><socio-demographics><sociodemographic predictors><sociodemographics><stigma><study design><success><surveillance study><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><systematic review><taste processing><taste response><therapeutic response><thoughts><tool><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2><transplant patient><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treatment provider><treatment research><treatment response><uptake><v mos><v-mos Gene><vaccin><vaccin protein><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination acceptability><vaccination acceptance><vaccination access><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination availability><vaccination confidence><vaccination hesitancy><vaccination study><vaccination trial><vaccination uptake><vaccination willingness><vaccine acceptability><vaccine acceptance><vaccine access><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine availability><vaccine confidence><vaccine deployment><vaccine development><vaccine distribution><vaccine efficacy><vaccine for novel coronavirus><vaccine formulation><vaccine hesitancy><vaccine hesitant><vaccine response><vaccine roll-out><vaccine rollout><vaccine safety><vaccine study><vaccine trial><vaccine uptake><vaccine willingness><virology><virtual community><web site><website><work-study>